Parenteral Manual

Clindamycin phosphate

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
DALACIN-C®
Classification: 
Antibiotic
Original Date: 
August 2005
Revised Date: 
May 2023
Indications: 
  • Treatment of serious infections due to sensitive anaerobic or gram positive bacteria
  • Bacterial endocarditis prophylaxis for dental and upper respiratory procedures in penicillin-allergic patients.
Reconstitution and Stability: 
  • Stable at room temperature
  • Bags available as 12 mg/mL solution
Compatibility: 

- Solutions Compatible: dextrose up to D10W, 0.9% NaCl, ringer's lactate

- Additives/Above Cassette Compatible: gentamicin, KCl (up to 100 mmol/L)

- Y-site Compatible: morphine, TPN

- Incompatible: aminophylline, tobramycin

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO
IM

YES
Usual dose: < 600 mg
IV Direct

NO
IV Intermittent Infusion

YES
Usual dilution: 12 mg/mL
Infusion time: 30-60 minutes
Infusion rate: do not exceed 30 mg/minute
IV Continuous Infusion YES

 

 

Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric:                         

  • 25-30 mg/kg/day IV ÷  Q 8 hours (Maximum: 1800 mg/day)
  • Severe Infection: 40 mg/kg/day ÷ Q 6 -8 hours (Maximum: 2700 mg/day)  - such as necrotizing fasciitis
  • Refer to CHEO guidelines for - Prevention of Bacterial Endocarditis
                                              - Antimicrobials for Surgical Prophylaxis

Adolescent/Adult:             

  • Usual dose: 1.2-2.7 g/day IV ÷ Q 6-12 hours

    Dosing Interval in hepatic impairment:

  • Half-life increases in moderate to severe liver dysfunction; dosage reductions are recommended; consult Pharmacy for guidelines.
Potential hazards of parenteral administration: 
  • Thrombophlebitis, local erythema, pain and swelling may occur at injection site
  • Hypersensitivity reactions - urticaria and rash
  • Occasional pain or abscess formation after IM injection
  • Hypotension and cardiopulmonary arrest may occur during rapid IV administration; infusion rate should not exceed 30 mg/min
  • Elevation of serum transaminases, transient leukopenia and eosinophilia
  • Clostridium difficile-associated diarrhea and pseudomembranous colitis have occurred
Notes: 
  • Does not cross blood-brain barrier even in the presence of inflamed meninges
  • Discontinue if severe diarrhea occurs; pseudomembranous colitis may develop even up to several weeks following discontinuation of therapy
  • Monitor changes in bowel frequency, CBC, liver and renal function tests

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.